Cannabinoid CB1 receptor antagonists.
- Published in:
- Drug Development Research, 2009, v. 70, n. 8, p. 525, doi. 10.1002/ddr.20332
- By:
- Publication type:
- Article
Works matching IS 02724391 AND DT 2009 AND VI 70 AND IP 8
Results: 7
1
2
Evaluation of taranabant (MK-0364) for its self-administration in rhesus monkeys and for its discriminative stimulus effects in rats.
- Published in:
- Drug Development Research, 2009, v. 70, n. 8, p. 577, doi. 10.1002/ddr.20336
- By:
- Publication type:
- Article
3
Are CB<sub>1</sub> receptor antagonists nootropic or cognitive impairing agents?
- Published in:
- Drug Development Research, 2009, v. 70, n. 8, p. 555, doi. 10.1002/ddr.20334
- By:
- Publication type:
- Article
4
CB1 receptor inverse agonist pharmacotherapy for metabolic disorders.
- Published in:
- Drug Development Research, 2009, v. 70, n. 8, p. 566, doi. 10.1002/ddr.20335
- By:
- Publication type:
- Article
5
Recent CB1 cannabinoid receptor antagonists and inverse agonists.
- Published in:
- Drug Development Research, 2009, v. 70, n. 8, p. 601, doi. 10.1002/ddr.20338
- By:
- Publication type:
- Article
6
Neuroanatomical basis for therapeutic applications of cannabinoid receptor 1 antagonists.
- Published in:
- Drug Development Research, 2009, v. 70, n. 8, p. 527, doi. 10.1002/ddr.20333
- By:
- Publication type:
- Article
7
Toward the design of cannabinoid CB<sub>1</sub> receptor inverse agonists and neutral antagonists.
- Published in:
- Drug Development Research, 2009, v. 70, n. 8, p. 585, doi. 10.1002/ddr.20337
- By:
- Publication type:
- Article